State-of-the-Art: Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus

Research output: Contribution to journalArticle

5 Scopus citations


Diabetes mellitus is a global pandemic, associated with a high burden of cardiovascular disease. There are multiple platelet derangements in patients with diabetes, and antiplatelet drugs remain the first-line agents for secondary prevention as well as for high-risk primary prevention among patients with diabetes. This review provides a summary of oral antiplatelet drug hypo-responsiveness in patients with diabetes, specifically aspirin and clopidogrel resistance. Topics discussed include antiplatelet testing, definitions used to define hypo-response and resistance, its prevalence, association with clinical outcomes, and strategies to mitigate resistance. The role of prasugrel and ticagrelor, as well as investigational agents, is also discussed.

Original languageEnglish (US)
JournalCurrent Cardiovascular Risk Reports
Issue number2
Publication statusPublished - 2015



  • Antiplatelet
  • Antiplatelet resistance
  • Aspirin resistance
  • Clopidogrel resistance
  • Diabetes mellitus
  • High on-treatment platelet reactivity
  • Platelets

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this